73738-7
Newborn screening test results panel - Point of Care
Active
Term Description
The newborn screening test results panel - point of care covers screening that is done at the bedside prior to the infant's discharge from the hospital. Whereas most newborn screening tests are run on dried blood spots, two (hearing screening and critical congenital heart disease screening) are done as point-of-care tests.
Panel Hierarchy
Details for each LOINC in Panel LHC-Forms
| LOINC | Name | R/O/C | Cardinality | Example UCUM Units |
|---|---|---|---|---|
| 73738-7 | Newborn screening test results panel - Point of Care | |||
| Indent54111-0 | Newborn hearing screening panel | |||
| Indent Indent57700-7 | Hearing loss newborn screening comment/discussion | |||
| Indent Indent58232-0 | Hearing loss risk indicators [Identifier] | |||
| Indent Indent54106-0 | Newborn hearing screen method | |||
| Indent Indent73741-1 | Newborn hearing screen panel - Left Ear | |||
| Indent Indent Indent54108-6 | Newborn hearing screen of Ear - left | |||
| Indent Indent Indent73740-3 | Screening duration of Ear - left | min | ||
| Indent Indent Indent73739-5 | Newborn hearing screen reason not performed of Ear - left | |||
| Indent Indent73744-5 | Newborn hearing screen panel - Right Ear | C | ||
| Indent Indent Indent54109-4 | Newborn hearing screen of Ear - right | R | 1..1 | |
| Indent Indent Indent73743-7 | Screening duration of Ear - right | C | 0..1 | min |
| Indent Indent Indent73742-9 | Newborn hearing screen reason not performed of Ear - right | C | 0..* | |
| Indent73805-4 | CCHD newborn screening panel | |||
| Indent Indent73700-7 | CCHD newborn screening interpretation | |||
| Indent Indent73696-7 | Oxygen saturation.preductal-oxygen saturation.postductal [Mass fraction difference] in Bld.preductal and Bld.postductal | % | ||
| Indent Indent73806-2 | Newborn age in hours | h | ||
| Indent Indent73699-1 | Number of prior CCHD screens [#] Qualitative | |||
| Indent Indent73804-7 | Oxygen saturation sensor name | |||
| Indent Indent73803-9 | Oxygen saturation sensor type | |||
| Indent Indent73802-1 | Oxygen saturation sensor wrap name | |||
| Indent Indent73801-3 | Oxygen saturation sensor wrap type | |||
| Indent Indent73800-5 | Oxygen saturation sensor wrap size | |||
| Indent Indent73697-5 | CCHD newborn screening protocol used [Type] | |||
| Indent Indent73698-3 | Reason CCHD oxygen saturation screening not performed | |||
| Indent Indent59407-7 | Oxygen saturation in Blood Preductal by Pulse oximetry | % | ||
| Indent Indent73799-9 | Heart rate Blood Preductal Pulse oximetry | /min | ||
| Indent Indent73798-1 | Perfusion index Blood Preductal Pulse oximetry | % | ||
| Indent Indent73797-3 | Signal quality Blood Preductal Pulse oximetry | |||
| Indent Indent73796-5 | Infant activity during preductal oxygen saturation measurement | |||
| Indent Indent59418-4 | Oxygen saturation in Blood Postductal by Pulse oximetry | % | ||
| Indent Indent73795-7 | Heart rate Blood Postductal Pulse oximetry | /min | ||
| Indent Indent73794-0 | Perfusion index Blood Postductal Pulse oximetry | % | ||
| Indent Indent73793-2 | Signal quality Blood Postductal Pulse oximetry | |||
| Indent Indent73792-4 | Infant activity during postductal oxygen saturation measurement | |||
| Indent58092-8 | Acylcarnitine newborn screen panel | C | ||
| Indent Indent58088-6 | Acylcarnitine newborn screen interpretation | C | ||
| Indent Indent58093-6 | Acylcarnitine newborn screening comment-discussion | C | ||
| Indent Indent57084-6 | Fatty acid oxidation newborn screen panel | C | ||
| Indent Indent Indent46736-5 | Fatty acid oxidation defects newborn screen interpretation | C | ||
| Indent Indent Indent57792-4 | Fatty acid oxidation conditions suspected [Identifier] in DBS | C | ||
| Indent Indent Indent57709-8 | Fatty acid oxidation defects newborn screening comment-discussion | C | ||
| Indent Indent Indent38481-8 | Carnitine free (C0) [Moles/volume] in DBS | C | umol/L | |
| Indent Indent Indent53233-3 | Carnitine free (C0)/Palmitoylcarnitine (C16) [Molar ratio] in DBS | C | {Ratio} | |
| Indent Indent Indent53234-1 | Carnitine free (C0)/Stearoylcarnitine (C18) [Molar ratio] in DBS | C | {Ratio} | |
| Indent Indent Indent53235-8 | Carnitine free (C0)/Palmitoylcarnitine (C16)+Stearoylcarnitine (C18) [Molar ratio] in DBS | C | {Ratio} | |
| Indent Indent Indent53236-6 | Carnitine.free (C0)+Acetylcarnitine (C2)+Propionylcarnitine (C3)+Palmitoylcarnitine (C16)+Oleoylcarnitine (C18:1)+Stearoylcarnitine (C18)/Citrulline [Molar ratio] in DBS | C | {Ratio} | |
| Indent Indent Indent75211-3 | Propionylcarnitine (C3)+Palmitoylcarnitine (C16) [Moles/volume] in DBS | C | umol/L | |
| Indent Indent Indent75212-1 | Malonylcarnitine (C3-DC)/Decanoylcarnitine (C10) [Molar ratio] in DBS | C | {ratio} | |
| Indent Indent Indent54462-7 | Malonylcarnitine (C3-DC) [Moles/volume] in DBS | C | umol/L | |
| Indent Indent Indent75213-9 | Malonylcarnitine (C3-DC)+3-Hydroxybutyrylcarnitine (C4-OH)/Decanoylcarnitine (C10) [Molar ratio] in DBS | C | {ratio} | |
| Indent Indent Indent50157-7 | Acetylcarnitine (C2) [Moles/volume] in DBS | C | umol/L | |
| Indent Indent Indent53166-5 | Butyrylcarnitine+Isobutyrylcarnitine (C4) [Moles/volume] in DBS | C | umol/L | |
| Indent Indent Indent53167-3 | Butyrylcarnitine+Isobutyrylcarnitine (C4)/Acetylcarnitine (C2) [Molar ratio] in DBS | C | {Ratio} | |
| Indent Indent Indent53168-1 | Butyrylcarnitine+Isobutyrylcarnitine (C4)/Propionylcarnitine (C3) [Molar ratio] in DBS | C | {Ratio} | |
| Indent Indent Indent53169-9 | Butyrylcarnitine+Isobutyrylcarnitine (C4)/Octanoylcarnitine (C8) [Molar ratio] in DBS | C | {Ratio} | |
| Indent Indent Indent50102-3 | 3-Hydroxybutyrylcarnitine (C4-OH) [Moles/volume] in DBS | C | umol/L | |
| Indent Indent Indent45211-0 | Hexanoylcarnitine (C6) [Moles/volume] in DBS | C | umol/L | |
| Indent Indent Indent53173-1 | 3-Hydroxyhexanoylcarnitine (C6-OH) [Moles/volume] in DBS | C | umol/L | |
| Indent Indent Indent45207-8 | Glutarylcarnitine (C5-DC) [Moles/volume] in DBS | C | umol/L | |
| Indent Indent Indent53174-9 | Octenoylcarnitine (C8:1) [Moles/volume] in DBS | C | umol/L | |
| Indent Indent Indent53175-6 | Octanoylcarnitine (C8) [Moles/volume] in DBS | C | umol/L | |
| Indent Indent Indent53176-4 | Octanoylcarnitine (C8)/Acetylcarnitine (C2) [Molar ratio] in DBS | C | {Ratio} | |
| Indent Indent Indent53177-2 | Octanoylcarnitine (C8)/Decanoylcarnitine (C10) [Molar ratio] in DBS | C | {Ratio} | |
| Indent Indent Indent53178-0 | 3-Hydroxyoctanoylcarnitine (C8-OH)+Malonylcarnitine (C3-DC) [Moles/volume] in DBS | C | umol/L | |
| Indent Indent Indent53402-4 | 3-Hydroxyoctanoylcarnitine (C8-OH)+Malonylcarnitine (C3-DC)/Butyrylcarnitine+Isobutyrylcarnitine (C4) [Molar ratio] in DBS | C | {Ratio} | |
| Indent Indent Indent53179-8 | 3-Hydroxyoctanoylcarnitine (C8-OH)+Malonylcarnitine (C3-DC)/Decanoylcarnitine (C10) [Molar ratio] in DBS | C | {Ratio} | |
| Indent Indent Indent53180-6 | Decadienoylcarnitine (C10:2) [Moles/volume] in DBS | C | umol/L | |
| Indent Indent Indent45198-9 | Decenoylcarnitine (C10:1) [Moles/volume] in DBS | C | umol/L | |
| Indent Indent Indent45197-1 | Decanoylcarnitine (C10) [Moles/volume] in DBS | C | umol/L | |
| Indent Indent Indent53182-2 | 3-Hydroxydecenoylcarnitine (C10:1-OH) [Moles/volume] in DBS | C | umol/L | |
| Indent Indent Indent53183-0 | Glutarylcarnitine (C5-DC)+3-Hydroxydecanoylcarnitine (C10-OH) [Moles/volume] in DBS | C | umol/L | |
| Indent Indent Indent53403-2 | Glutarylcarnitine (C5-DC)+3-Hydroxydecanoylcarnitine (C10-OH)/Butyrylcarnitine+Isobutyrylcarnitine (C4) [Molar ratio] in DBS | C | {Ratio} | |
| Indent Indent Indent53184-8 | Glutarylcarnitine (C5-DC)+3-Hydroxydecanoylcarnitine (C10-OH)/3-Hydroxyisovalerylcarnitine (C5-OH) [Molar ratio] in DBS | C | {Ratio} | |
| Indent Indent Indent53185-5 | Glutarylcarnitine (C5-DC)+3-Hydroxydecanoylcarnitine (C10-OH)/Octanoylcarnitine (C8) [Molar ratio] in DBS | C | {Ratio} | |
| Indent Indent Indent53186-3 | Glutarylcarnitine (C5-DC)+3-Hydroxydecanoylcarnitine (C10-OH)/Palmitoylcarnitine (C16) [Molar ratio] in DBS | C | {Ratio} | |
| Indent Indent Indent45200-3 | Dodecenoylcarnitine (C12:1) [Moles/volume] in DBS | C | umol/L | |
| Indent Indent Indent45199-7 | Dodecanoylcarnitine (C12) [Moles/volume] in DBS | C | umol/L | |
| Indent Indent Indent53188-9 | 3-Hydroxydodecenoylcarnitine (C12:1-OH) [Moles/volume] in DBS | C | umol/L | |
| Indent Indent Indent53189-7 | 3-Hydroxydodecanoylcarnitine (C12-OH) [Moles/volume] in DBS | C | umol/L | |
| Indent Indent Indent53190-5 | Tetradecadienoylcarnitine (C14:2) [Moles/volume] in DBS | C | umol/L | |
| Indent Indent Indent53191-3 | Tetradecenoylcarnitine (C14:1) [Moles/volume] in DBS | C | umol/L | |
| Indent Indent Indent53192-1 | Tetradecanoylcarnitine (C14) [Moles/volume] in DBS | C | umol/L | |
| Indent Indent Indent53193-9 | Tetradecenoylcarnitine (C14:1)/Acetylcarnitine (C2) [Molar ratio] in DBS | C | {Ratio} | |
| Indent Indent Indent53194-7 | Tetradecenoylcarnitine (C14:1)/Dodecenoylcarnitine (C12:1) [Molar ratio] in DBS | C | {Ratio} | |
| Indent Indent Indent53195-4 | Tetradecenoylcarnitine (C14:1)/Palmitoylcarnitine (C16) [Molar ratio] in DBS | C | {Ratio} | |
| Indent Indent Indent70159-9 | Tetradecenoylcarnitine (C14:1)/Tetradecanoylcarnitine (C14) [Molar ratio] in DBS | C | {ratio} | |
| Indent Indent Indent53196-2 | 3-Hydroxytetradecadienoylcarnitine (C14:2-OH) [Moles/volume] in DBS | C | umol/L | |
| Indent Indent Indent53197-0 | 3-Hydroxytetradecenoylcarnitine (C14:1-OH) [Moles/volume] in DBS | C | umol/L | |
| Indent Indent Indent50281-5 | 3-Hydroxytetradecanoylcarnitine (C14-OH) [Moles/volume] in DBS | C | umol/L | |
| Indent Indent Indent53198-8 | Palmitoleylcarnitine (C16:1) [Moles/volume] in DBS | C | umol/L | |
| Indent Indent Indent53199-6 | Palmitoylcarnitine (C16) [Moles/volume] in DBS | C | umol/L | |
| Indent Indent Indent50121-3 | 3-Hydroxypalmitoleylcarnitine (C16:1-OH) [Moles/volume] in DBS | C | umol/L | |
| Indent Indent Indent50125-4 | 3-Hydroxypalmitoylcarnitine (C16-OH) [Moles/volume] in DBS | C | umol/L | |
| Indent Indent Indent53201-0 | 3-Hydroxypalmitoylcarnitine (C16-OH)/Palmitoylcarnitine (C16) [Molar ratio] in DBS | C | {Ratio} | |
| Indent Indent Indent45217-7 | Linoleoylcarnitine (C18:2) [Moles/volume] in DBS | C | umol/L | |
| Indent Indent Indent53202-8 | Oleoylcarnitine (C18:1) [Moles/volume] in DBS | C | umol/L | |
| Indent Indent Indent53241-6 | Stearoylcarnitine (C18) [Moles/volume] in DBS | C | umol/L | |
| Indent Indent Indent53400-8 | Stearoylcarnitine (C18)/Propionylcarnitine (C3) [Molar ratio] in DBS | C | {Ratio} | |
| Indent Indent Indent50109-8 | 3-Hydroxylinoleoylcarnitine (C18:2-OH) [Moles/volume] in DBS | C | umol/L | |
| Indent Indent Indent50113-0 | 3-Hydroxyoleoylcarnitine (C18:1-OH) [Moles/volume] in DBS | C | umol/L | |
| Indent Indent Indent50132-0 | 3-Hydroxystearoylcarnitine (C18-OH) [Moles/volume] in DBS | C | umol/L | |
| Indent Indent Indent53836-3 | ABCD1 gene targeted mutation analysis in Blood or Tissue by Molecular genetics method | |||
| Indent Indent57085-3 | Organic acid newborn screen panel | C | ||
| Indent Indent Indent46744-9 | Organic acidemias newborn screen interpretation | C | ||
| Indent Indent Indent57791-6 | Organic acidemia conditions suspected [Identifier] in DBS | C | ||
| Indent Indent Indent57708-0 | Organic acidemias defects newborn screening comment-discussion | C | ||
| Indent Indent Indent50157-7 | Acetylcarnitine (C2) [Moles/volume] in DBS | C | umol/L | |
| Indent Indent Indent53237-4 | Acrylylcarnitine (C3:1) [Moles/volume] in DBS | C | umol/L | |
| Indent Indent Indent53160-8 | Propionylcarnitine (C3) [Moles/volume] in DBS | C | umol/L | |
| Indent Indent Indent53161-6 | Propionylcarnitine (C3)/Methionine [Molar ratio] in DBS | C | {Ratio} | |
| Indent Indent Indent53162-4 | Propionylcarnitine (C3)/Carnitine.free (C0) [Molar ratio] in DBS | C | {Ratio} | |
| Indent Indent Indent53163-2 | Propionylcarnitine (C3)/Acetylcarnitine (C2) [Molar ratio] in DBS | C | {Ratio} | |
| Indent Indent Indent54462-7 | Malonylcarnitine (C3-DC) [Moles/volume] in DBS | C | umol/L | |
| Indent Indent Indent67708-8 | Malonylcarnitine (C3-DC)+3-Hydroxybutyrylcarnitine (C4-OH) [Moles/volume] in DBS | C | umol/L | |
| Indent Indent Indent75213-9 | Malonylcarnitine (C3-DC)+3-Hydroxybutyrylcarnitine (C4-OH)/Decanoylcarnitine (C10) [Molar ratio] in DBS | C | {ratio} | |
| Indent Indent Indent53164-0 | Propionylcarnitine (C3)/Palmitoylcarnitine (C16) [Molar ratio] in DBS | C | {Ratio} | |
| Indent Indent Indent53166-5 | Butyrylcarnitine+Isobutyrylcarnitine (C4) [Moles/volume] in DBS | C | umol/L | |
| Indent Indent Indent53167-3 | Butyrylcarnitine+Isobutyrylcarnitine (C4)/Acetylcarnitine (C2) [Molar ratio] in DBS | C | {Ratio} | |
| Indent Indent Indent53168-1 | Butyrylcarnitine+Isobutyrylcarnitine (C4)/Propionylcarnitine (C3) [Molar ratio] in DBS | C | {Ratio} | |
| Indent Indent Indent53169-9 | Butyrylcarnitine+Isobutyrylcarnitine (C4)/Octanoylcarnitine (C8) [Molar ratio] in DBS | C | {Ratio} | |
| Indent Indent Indent53170-7 | Tiglylcarnitine (C5:1) [Moles/volume] in DBS | C | umol/L | |
| Indent Indent Indent45207-8 | Glutarylcarnitine (C5-DC) [Moles/volume] in DBS | C | umol/L | |
| Indent Indent Indent75216-2 | Glutarylcarnitine (C5-DC)/Malonylcarnitine (C3-DC) [Molar ratio] in DBS | {ratio} | ||
| Indent Indent Indent67701-3 | Glutarylcarnitine (C5-DC)+3-Hydroxyhexanoylcarnitine (C6-OH)/Palmitoylcarnitine (C16) [Molar ratio] in DBS | C | {Ratio} | |
| Indent Indent Indent67710-4 | Glutarylcarnitine (C5-DC)+3-Hydroxyhexanoylcarnitine (C6-OH) [Moles/volume] in DBS | C | umol/L | |
| Indent Indent Indent67711-2 | Glutarylcarnitine (C5-DC)+3-Hydroxyhexanoylcarnitine (C6-OH)/Octanoylcarnitine (C8) [Molar ratio] in DBS | C | {Ratio} | |
| Indent Indent Indent45216-9 | Isovalerylcarnitine+Methylbutyrylcarnitine (C5) [Moles/volume] in DBS | C | umol/L | |
| Indent Indent Indent53238-2 | Isovalerylcarnitine+Methylbutyrylcarnitine (C5)/Carnitine.free (C0) [Molar ratio] in DBS | C | {Ratio} | |
| Indent Indent Indent53239-0 | Isovalerylcarnitine+Methylbutyrylcarnitine (C5)/Acetylcarnitine (C2) [Molar ratio] in DBS | C | {Ratio} | |
| Indent Indent Indent53240-8 | Isovalerylcarnitine+Methylbutyrylcarnitine (C5)/Propionylcarnitine (C3) [Molar ratio] in DBS | C | {Ratio} | |
| Indent Indent Indent53401-6 | Isovalerylcarnitine+Methylbutyrylcarnitine (C5)/Octanoylcarnitine (C8) [Molar ratio] in DBS | C | {Ratio} | |
| Indent Indent Indent50106-4 | 3-Hydroxyisovalerylcarnitine (C5-OH) [Moles/volume] in DBS | C | umol/L | |
| Indent Indent Indent53171-5 | 3-Hydroxyisovalerylcarnitine (C5-OH)/Carnitine.free (C0) [Molar ratio] in DBS | C | {Ratio} | |
| Indent Indent Indent53172-3 | 3-Hydroxyisovalerylcarnitine (C5-OH)/Octanoylcarnitine (C8) [Molar ratio] in DBS | C | {Ratio} | |
| Indent Indent Indent53178-0 | 3-Hydroxyoctanoylcarnitine (C8-OH)+Malonylcarnitine (C3-DC) [Moles/volume] in DBS | C | umol/L | |
| Indent Indent Indent53402-4 | 3-Hydroxyoctanoylcarnitine (C8-OH)+Malonylcarnitine (C3-DC)/Butyrylcarnitine+Isobutyrylcarnitine (C4) [Molar ratio] in DBS | C | {Ratio} | |
| Indent Indent Indent53179-8 | 3-Hydroxyoctanoylcarnitine (C8-OH)+Malonylcarnitine (C3-DC)/Decanoylcarnitine (C10) [Molar ratio] in DBS | C | {Ratio} | |
| Indent Indent Indent45222-7 | Methylmalonylcarnitine (C4-DC) [Moles/volume] in DBS | C | umol/L | |
| Indent Indent Indent67709-6 | Methylmalonylcarnitine (C4-DC)+3-Hydroxyisovalerylcarnitine (C5-OH) [Moles/volume] in DBS | C | umol/L | |
| Indent Indent Indent53181-4 | Methylmalonylcarnitine (C4-DC)/3-Hydroxyisovalerylcarnitine (C5-OH) [Molar ratio] in DBS | C | {Ratio} | |
| Indent Indent Indent53183-0 | Glutarylcarnitine (C5-DC)+3-Hydroxydecanoylcarnitine (C10-OH) [Moles/volume] in DBS | C | umol/L | |
| Indent Indent Indent53403-2 | Glutarylcarnitine (C5-DC)+3-Hydroxydecanoylcarnitine (C10-OH)/Butyrylcarnitine+Isobutyrylcarnitine (C4) [Molar ratio] in DBS | C | {Ratio} | |
| Indent Indent Indent53184-8 | Glutarylcarnitine (C5-DC)+3-Hydroxydecanoylcarnitine (C10-OH)/3-Hydroxyisovalerylcarnitine (C5-OH) [Molar ratio] in DBS | C | {Ratio} | |
| Indent Indent Indent53185-5 | Glutarylcarnitine (C5-DC)+3-Hydroxydecanoylcarnitine (C10-OH)/Octanoylcarnitine (C8) [Molar ratio] in DBS | C | {Ratio} | |
| Indent Indent Indent53186-3 | Glutarylcarnitine (C5-DC)+3-Hydroxydecanoylcarnitine (C10-OH)/Palmitoylcarnitine (C16) [Molar ratio] in DBS | C | {Ratio} | |
| Indent Indent Indent53187-1 | Methylglutarylcarnitine (C6-DC) [Moles/volume] in DBS | C | umol/L | |
| Indent Indent Indent53165-7 | Formiminoglutamate [Moles/volume] in DBS | C | umol/L | |
| Indent54078-1 | Cystic fibrosis newborn screening panel | C | ||
| Indent Indent46769-6 | Cystic fibrosis newborn screen interpretation | R | 1..1 | |
| Indent Indent57707-2 | Cystic fibrosis newborn screening comment-discussion | C | ||
| Indent Indent54083-1 | CFTR gene mutations found [Identifier] in DBS by Targeted gene mutation analysis Nominal | C | ||
| Indent Indent2077-6 | Chloride [Moles/volume] in Sweat | C | mmol/L | |
| Indent Indent48633-2 | Trypsinogen I Free [Mass/volume] in DBS | C | ug/L | |
| Indent54076-5 | Endocrine newborn screening panel | C | ||
| Indent Indent57086-1 | Congenital adrenal hyperplasia newborn screening panel | C | ||
| Indent Indent Indent46758-9 | Congenital adrenal hyperplasia newborn screen interpretation | R | 1..1 | |
| Indent Indent Indent57706-4 | Congenital adrenal hyperplasia newborn screening comment-discussion | C | ||
| Indent Indent Indent53347-1 | 11-Deoxycorticosterone [Mass/volume] in DBS | C | ng/dL | |
| Indent Indent Indent53338-0 | 11-Deoxycortisol [Mass/volume] in DBS | C | ug/dL | |
| Indent Indent Indent38473-5 | 17-Hydroxyprogesterone [Mass/volume] in DBS | C | ng/mL | |
| Indent Indent Indent53336-4 | 17-Hydroxyprogesterone+Androstenedione/Cortisol [Mass Ratio] in DBS | C | {ratio} | |
| Indent Indent Indent53341-4 | 21-Deoxycortisol [Mass/volume] in DBS | C | ug/dL | |
| Indent Indent Indent53343-0 | Androstenedione [Mass/volume] in DBS | C | ng/dL | |
| Indent Indent Indent53345-5 | Cortisol [Mass/volume] in DBS | C | ug/dL | |
| Indent Indent54090-6 | Thyroid newborn screening panel | C | ||
| Indent Indent Indent46762-1 | Congenital hypothyroidism newborn screen interpretation | R | ||
| Indent Indent Indent57705-6 | Congenital hypothyroidism newborn screening comment-discussion | C | ||
| Indent Indent Indent31144-9 | Thyroxine (T4) [Mass/volume] in DBS | C | ug/dL | |
| Indent Indent Indent29575-8 | Thyrotropin [Units/volume] in DBS | C | m[IU]/L | |
| Indent54079-9 | Galactosemia newborn screening panel | C | ||
| Indent Indent46737-3 | Galactosemias newborn screen interpretation | R | 1..1 | |
| Indent Indent57704-9 | Galactosemias newborn screening comment-discussion | C | ||
| Indent Indent54084-9 | Galactose [Mass/volume] in DBS | C | mg/dL | |
| Indent Indent33288-2 | Galactose 1 phosphate uridyl transferase [Presence] in DBS | C | ||
| Indent Indent42906-8 | Galactose 1 phosphate uridyl transferase [Enzymatic activity/volume] in DBS | C | nmol/h/mL | |
| Indent Indent40842-7 | Galactose 1 phosphate [Mass/volume] in DBS | C | mg/dL | |
| Indent54081-5 | Hemoglobinopathies newborn screening panel | C | ||
| Indent Indent64116-7 | Hemoglobin observations newborn screening panel | |||
| Indent Indent Indent64122-5 | Hemoglobins that can be presumptively identified based on available controls in DBS | C | ||
| Indent Indent Indent64117-5 | Most predominant hemoglobin in DBS | C | ||
| Indent Indent Indent64118-3 | Second most predominant hemoglobin in DBS | C | ||
| Indent Indent Indent64119-1 | Third most predominant hemoglobin in DBS | C | ||
| Indent Indent Indent64120-9 | Fourth most predominant hemoglobin in DBS | C | ||
| Indent Indent Indent64121-7 | Fifth most predominant hemoglobin in DBS | C | ||
| Indent Indent46740-7 | Hemoglobin disorders newborn screen interpretation | R | 1..1 | |
| Indent Indent57703-1 | Hemoglobin disorders newborn screening comment-discussion | C | ||
| Indent Indent71592-0 | Hemoglobinopathies conditions suspected [Identifier] in DBS | C | ||
| Indent Indent54072-4 | Hemoglobin A/Hemoglobin.total in DBS | C | % | |
| Indent Indent54069-0 | Hemoglobin Barts/Hemoglobin.total in DBS | C | % | |
| Indent Indent54073-2 | Hemoglobin C/Hemoglobin.total in DBS | C | % | |
| Indent Indent54070-8 | Hemoglobin D/Hemoglobin.total in DBS | C | % | |
| Indent Indent54071-6 | Hemoglobin E/Hemoglobin.total in DBS | C | % | |
| Indent Indent54074-0 | Hemoglobin F/Hemoglobin.total in DBS | C | % | |
| Indent Indent54068-2 | Hemoglobin O - Arab/Hemoglobin.total in DBS | C | % | |
| Indent Indent56476-5 | Hemoglobin S/Hemoglobin.total in DBS | C | % | |
| Indent54082-3 | Infectious diseases newborn screening panel | C | ||
| Indent Indent57702-3 | Infectious diseases newborn screen interpretation | R | 1..1 | |
| Indent Indent57701-5 | Infectious diseases newborn screening comment-discussion | C | ||
| Indent Indent54086-4 | HIV 1+2 IgG Ab [Presence] in DBS | C | ||
| Indent Indent54087-2 | Toxoplasma gondii IgG Ab [Presence] in DBS | C | ||
| Indent Indent54088-0 | Toxoplasma gondii IgM Ab [Presence] in DBS | C | ||
| Indent Indent88535-0 | Cytomegalovirus DNA [Presence] in DBS by NAA with probe detection | |||
| Indent57087-9 | Biotinidase newborn screening panel | C | ||
| Indent Indent46761-3 | Biotinidase deficiency newborn screen interpretation | R | 1..1 | |
| Indent Indent57699-1 | Biotinidase deficiency newborn screening comment-discussion | C | ||
| Indent Indent38478-4 | Biotinidase [Presence] in DBS | C | ||
| Indent Indent75217-0 | Biotinidase [Enzymatic activity/volume] in DBS | C | nmol/mL/min | |
| Indent58091-0 | Glucose-6-Phosphate dehydrogenase newborn screen panel | C | ||
| Indent Indent58089-4 | Glucose-6-Phosphate dehydrogenase newborn screen interpretation | C | ||
| Indent Indent58090-2 | Glucose-6-Phosphate dehydrogenase newborn screening comment-discussion | C | ||
| Indent Indent33287-4 | Glucose-6-Phosphate dehydrogenase [Presence] in DBS | C | ||
| Indent62300-9 | Lysosomal disorders newborn screening panel | C | ||
| Indent Indent62301-7 | Lysosomal disorders newborn screen interpretation | C | 0..1 | |
| Indent Indent62303-3 | Lysosomal disorders newborn screening comment-discussion | C | 0..1 | |
| Indent Indent62302-5 | Lysosomal disorders suspected [Identifier] in DBS | C | 0..1 | |
| Indent Indent62304-1 | Fabry disease newborn screening panel | C | ||
| Indent Indent Indent62305-8 | Fabry disease newborn screen interpretation | R | 0..1 | |
| Indent Indent Indent62306-6 | Fabry disease newborn screening comment-discussion | C | 0..1 | |
| Indent Indent Indent55908-8 | Alpha galactosidase A [Enzymatic activity/volume] in DBS | C | 0..1 | umol/L/h |
| Indent Indent62307-4 | Krabbe disease newborn screening panel | C | ||
| Indent Indent Indent62308-2 | Krabbe disease newborn screen interpretation | R | 0..1 | |
| Indent Indent Indent62309-0 | Krabbe disease newborn screening comment-discussion | C | 0..1 | |
| Indent Indent Indent62310-8 | Galactosylceramidase [Enzymatic activity/volume] in DBS | C | 0..1 | umol/L/h |
| Indent Indent62311-6 | Gaucher disease newborn screening panel | C | ||
| Indent Indent Indent62312-4 | Gaucher disease newborn screen interpretation | R | 0..1 | |
| Indent Indent Indent62313-2 | Gaucher disease newborn screening comment-discussion | C | 0..1 | |
| Indent Indent Indent55917-9 | Glucosylceramidase [Enzymatic activity/volume] in DBS | C | 0..* | umol/L/h |
| Indent Indent79563-3 | Mucopolysaccharidosis type I newborn screening panel | |||
| Indent Indent Indent55909-6 | Alpha-L-iduronidase [Enzymatic activity/volume] in DBS | umol/h/L | ||
| Indent Indent Indent79564-1 | Mucopolysaccharidosis type I newborn screen interpretation | |||
| Indent Indent Indent79565-8 | Mucopolysaccharidosis type I newborn screening comment-discussion | |||
| Indent Indent104188-8 | Mucopolysaccharidosis type II newborn screening panel | |||
| Indent Indent Indent79462-8 | Iduronate-2-Sulfatase [Enzymatic activity/volume] in DBS | nmol/h/mL | ||
| Indent Indent Indent104190-4 | Mucopolysaccharidosis type II comment [Text] in DBS Narrative | |||
| Indent Indent Indent104189-6 | Mucopolysaccharidosis type II newborn screen interpretation newborn screen interpretation | |||
| Indent Indent62315-7 | Niemann Pick disease A/B newborn screening panel | C | ||
| Indent Indent Indent62318-1 | Niemann Pick disease A/B newborn screen interpretation | R | 0..1 | |
| Indent Indent Indent62319-9 | Niemann Pick disease A/B newborn screening comment-discussion | C | 0..1 | |
| Indent Indent Indent62316-5 | Acid sphingomyelinase [Enzymatic activity/volume] in DBS | C | 0..1 | umol/L/h |
| Indent Indent63414-7 | Pompe disease newborn screening panel | C | ||
| Indent Indent Indent63415-4 | Pompe disease newborn screen interpretation | R | 0..* | |
| Indent Indent Indent63416-2 | Pompe disease newborn screening comment-discussion | C | 0..* | |
| Indent Indent Indent55827-0 | Acid alpha glucosidase [Enzymatic activity/volume] in DBS | C | 0..* | umol/L/h |
| Indent Indent111825-6 | Metachromatic Leukodystrophy newborn screening panel | |||
| Indent Indent Indent111823-1 | Metachromatic leukodystrophy comment [Text] in DBS Narrative | |||
| Indent Indent Indent111822-3 | Metachromatic leukodystrophy comment newborn screen interpretation | |||
| Indent Indent Indent111824-9 | Cerebroside sulfatase [Enzymatic activity/volume] in DBS | U/L | ||
| Indent Indent Indent112305-8 | C16:0 sulfatide [Mass/volume] in DBS | ng/mL | ||
| Indent Indent Indent112304-1 | C16:1-OH sulfatide [Mass/volume] in DBS | ng/mL | ||
| Indent62333-0 | Severe combined immunodeficiency (SCID) newborn screening panel | C | ||
| Indent Indent62321-5 | Severe combined immunodeficiency newborn screen interpretation | R | 1..1 | |
| Indent Indent62322-3 | Severe combined immunodeficiency newborn screening comment-discussion | C | 0..1 | |
| Indent Indent62320-7 | T-cell receptor excision circle [#/volume] in DBS by NAA with probe detection | C | 0..1 | {copies} |
| Indent Indent92006-6 | T-cell receptor excision circle [Cycle Threshold #] in DBS | {Ct_value} | ||
| Indent Indent92007-4 | T-cell receptor excision circle [Z-score] in DBS | {Zscore} | ||
| Indent Indent92008-2 | T-cell receptor excision circle [Multiple of the median] in DBS | {M.o.M} | ||
| Indent92005-8 | Spinal muscular atrophy newborn screening panel | |||
| Indent Indent92004-1 | Spinal muscular atrophy newborn screen interpretation | |||
| Indent Indent92003-3 | Spinal muscular atrophy newborn screening comment-discussion | |||
| Indent Indent92002-5 | SMN1 gene [Cycle Threshold #] in DBS by NAA with probe detection | {Ct_value} | ||
| Indent Indent97654-8 | SMN2 gene copy number in Blood or Tissue by Molecular genetics method | {#} | ||
| Indent85267-3 | X-linked adrenoleukodystrophy (X-ALD) newborn screening panel | C | 0..1 | |
| Indent Indent85269-9 | X-linked adrenoleukodystrophy newborn screen interpretation | C | 0..* | |
| Indent Indent85268-1 | X-linked adrenoleukodystrophy newborn screening comment-discussion | C | 0..* | |
| Indent Indent79321-6 | Lysophosphatidylcholine(26:0) [Moles/volume] in DBS | O | 0..1 | umol/L |
| Indent57717-1 | Newborn screen card data panel | C | ||
| Indent Indent57716-3 | State printed on filter paper card [Identifier] in NBS card | R | ||
| Indent Indent79566-6 | Collection method - DBS | O | ||
| Indent Indent8339-4 | Birthweight | R | [lb_av];kg;g | |
| Indent Indent58229-6 | Body weight Measured --when specimen taken | O | [lb_av];kg | |
| Indent Indent57715-5 | Time of birth | R | {clock_time} | |
| Indent Indent73806-2 | Newborn age in hours | O | h | |
| Indent Indent57722-1 | Birth plurality of Pregnancy | R | ||
| Indent Indent57714-8 | Obstetric estimation of gestational age | R | wk | |
| Indent Indent57713-0 | Infant factors that affect newborn screening interpretation | R | 1..* | |
| Indent Indent67703-9 | Other infant factors that affect newborn screening interpretation Narrative | C | 0..* | |
| Indent Indent67706-2 | Maternal factors that affect newborn screening interpretation | O | 0..* | |
| Indent Indent67707-0 | Other maternal factors that affect newborn screening interpretation Narrative | C | 0..* | |
| Indent Indent77739-1 | Mother's Hepatitis B virus surface Ag status | C | ||
| Indent Indent57712-2 | Highest level of education Mother | O | 0..1 | |
| Indent Indent67704-7 | Feeding types | R | 1..* | |
| Indent Indent67705-4 | Other feeding types Narrative | C | 0..* | |
| Indent Indent79569-0 | Blood product given [Type] | C | ||
| Indent Indent62317-3 | Date of last blood product transfusion | O | 0..1 | |
| Indent Indent58232-0 | Hearing loss risk indicators [Identifier] | C | 1..* | |
| Indent Indent54106-0 | Newborn hearing screen method | C | ||
| Indent Indent54108-6 | Newborn hearing screen of Ear - left | C | ||
| Indent Indent54109-4 | Newborn hearing screen of Ear - right | C | ||
| Indent Indent73700-7 | CCHD newborn screening interpretation | C | ||
| Indent Indent73698-3 | Reason CCHD oxygen saturation screening not performed | C | ||
| Indent Indent57723-9 | Unique bar code number of Current sample | R | ||
| Indent Indent57711-4 | Unique bar code number of Initial sample | C | ||
| Indent Indent62323-1 | Post-discharge provider ID [Identifier] | C | 0..1 | |
| Indent Indent62324-9 | Post-discharge provider name in Provider | C | 0..1 | |
| Indent Indent62325-6 | Post-discharge provider practice ID | C | 0..1 | |
| Indent Indent62326-4 | Post-discharge provider practice name | C | 0..1 | |
| Indent Indent62327-2 | Post-discharge provider practice address | C | 0..1 | |
| Indent Indent62328-0 | Post-discharge provider practice phone number | C | 0..1 | |
| Indent Indent62329-8 | Birth hospital facility ID | C | 0..1 | |
| Indent Indent62330-6 | Birth hospital facility name | C | 0..1 | |
| Indent Indent62331-4 | Birth hospital facility address | C | 0..1 | |
| Indent Indent62332-2 | Birth hospital facility phone number | C | 0..1 |
LOINC Names Get Info
- Fully-Specified Name
- Newborn screening test results panel:
-: Pt: ^Patient: -: - Long Common Name
- Newborn screening test results panel - Point of Care
- Short Name
- NBS test results pnl - POC
Part Model Get Info
- Component
- Newborn screening test results panel
LP97728-7
- Analyte
- Newborn screening test results panel
LP97728-7
- Challenge
- NULL
- Adjustment
- NULL
- Count
- NULL
- Property
- -
LP6769-6
- Time
- Pt
LP6960-1
- Time Core
- Pt
LP6960-1
- Time Modifier
- NULL
- System
- ^Patient
LP310005-6
- System Core
- NULL
- Super System
- Patient
LP6985-8
- Scale
- -
LP7747-1
- Method
- NULL
Basic Attributes
- Class
- PANEL.H&P
- Type
- Clinical
- First Released
- Version 2.44
- Last Updated
- Version 2.77 (PANEL)
- Order vs. Observation
- Order
- Panel Type
- Organizer
Member of these Panels
| LOINC | Long Common Name |
|---|---|
| 54089-8 | Newborn screening panel American Health Information Community (AHIC) |
Language Variants Get Info
| Tag | Language | Translation |
|---|---|---|
| el-GR | Greek (Greece) | Πίνακας αποτελεσμάτων εξετάσεων διαλογής νεογνών: Synonyms: - PANEL.H& |
| es-ES | Spanish (Spain) | Panel de resultados de tests de cribado del recién nacido: |
| es-MX | Spanish (Mexico) | Panel de resultados de la prueba de detección del recién nacido: |
| fr-FR | French (France) | Dépistage néonatal - Résultats des tests panel: |
| it-IT | Italian (Italy) | Screening neonatale, panel risultati test: Synonyms: Panel risultati test di screening neonatale paziente Punto nel tempo (episodio) Set di prescrizione per anamnesi e esame obiettivo |
| nl-NL | Dutch (Netherlands) | pasgeborene screening testresultaten panel: |
| pl-PL | Polish (Poland) | Panel wyników badań przesiewowych noworodków: |
| ru-RU | Russian (Russian Federation) | Новорождённый скрининг тест результаты панель: Synonyms: Точка во времени; |
| zh-CN | Chinese (China) | 新生儿筛查试验结果组套: Synonyms: Asympt SCN 医嘱套餐 医嘱套餐类 医嘱套餐组 医嘱组 医嘱组.病史与体格检查小节; |
LOINC Terminology Service (API) using HL7® FHIR® Get Info
Requests to this service require a free LOINC username and password. Below is a sample of the possible capabilities. See the LOINC Terminology Service documentation for more information.
- CodeSystem lookup
- https:
//fhir.loinc.org/CodeSystem/$lookup?system=http: //loinc.org&code=73738-7 - Questionnaire definition
- https:
//fhir.loinc.org/Questionnaire/?url=http: //loinc.org/q/73738-7
LOINC Copyright
Copyright © Regenstrief Institute, Inc. All Rights Reserved. To the extent included herein, the LOINC table and LOINC codes are copyright © Regenstrief Institute, Inc. and the Logical Observation Identifiers Names and Codes (LOINC) Committee. See https://